TANTALIZING PRESENTATION OF NEW TECHNOLOGIES!

Presentations from GSK, Broad Institute, Indiana University on RNA-Seq

Izzy Scott-Moncrieff	6:05 AM (6 hours ago)
to me

  Dear Mutombo,

Sick of my emails? Bear with me. Because this week I have something very exciting for you.  Not one, or even two, but THREE PRESENTATIONS from the inaugural RNA-Seq 2013 meeting  that took place in Boston earlier this year. Have a read through the summaries below. Which gets your number 1 vote? We’re running  a poll on our Linkedin page (search Linkedin groups for RNA-Seq Forum) to establish which,  of groups from GSK, Broad Institute or Indiana University School of Medicine are engrossed  in the most exciting work at the moment.  Numéro un (1). Ganesh Sathe, DNA Sequencing Manager, GSK. “Applications of RNA-Seq within Research & Development at GSK” Ganesh spoke about using RNA-Seq for cancer target identification using very small amount of starting material. How GSK are going about sequencing blood samples for biomarker identification. Which new technologies are they using for cell line validation? Download the presentation here for free Numero due (2). Brian Haas, Senior Computational Biologist, Broad Institute “Trinity de novo RNA-Seq Assembly for Analysis of Model and Non-Model Organisms” Brain gave a fascinating comparison of Trinity software when used with model and non-model organisms. An overview of how, in the absence of a reference genome , this software coupled with companion utilities enables de novo transcript reconstruction. And subsequently how this yields insights into gene content and transcriptional regulation.  Free download of the presentation here Nummer drei (3). Yunlong Liu, Assistant Professor, Medical and Molecular Genetics,  Indiana University  “Statistical Modelling in Non-Coding RNA Mediated Regulatory Networks” Yunlong presents a bioinformatics strategy to construct the microRNA mediated regulatory network using genome-wide binding patterns of transcription factors. As well as this, brand new findings on long noncoding RNA in determining alcohol dependence in rat brains, using RNA-seq derived transcriptome mapping data.  You know the drill by now. Click here to download the presentation And if you thought that was all, not at all! These three presentations are brought you in  the run up to RNA-Seq Europe (3-5 December, Basel), where we’ll be bringing you even more top rate presentations on everything RNA-Seq. Make sure you check out the brochure. Remember, visit the Linkedin group to cast your vote on which is your number 1  presentation. As per, drop me a reply if you want more info on how to register. You can also send  me your vote directly. Maybe your company will hit the top spot next year… Bye for now! Izzy  Genomics Programme Director Hanson Wade P.S If you like the free presentations then check out the RNA-Seq website. You can peruse  the other exciting bits of RNA-Seq themed content there.

DO NOT CLAIM THAT I DID NOT TELL YOU (FYI)

DO NOT CLAIM THAT I DID NOT TELL YOU (FYI)

From: Health Alert Network (CDC) [mailto:healthalert@cdc.gov]
Sent: Friday, April 05, 2013 1:24 PM
To: Health Alert Network (CDC)
Subject: Errata for CDC HAN 344: Human Infections with Novel Influenza A (H7N9) Viruses

Dear HAN Coordinators,

Please see the two errata below that need to be incorporated into cascaded notification of CDC HAN 344. In the Treatment section the comma between oseltamivir and inhaled zanamivir was removed and replaced with the word or.  This change is important for clinical reasons.  In the For More Information section the typo in the final link to source should be corrected from Veterans to Veterinarians.

Treatment
    For persons hospitalized with suspected influenza, including suspected novel H7N9 virus infection, clinicians should start empiric treatment with influenza antiviral medications (oral oseltamivir or inhaled zanamivir) as soon as possible, without waiting for laboratory confirmation.
    For high-risk persons (persons <5 years of age, ≥65 years of age, and those with certain underlying medical conditions) with suspected influenza of any severity , including suspected novel H7N9 virus infection, clinicians should start empiric treatment with influenza antiviral medications (oral oseltamivir or inhaled zanamivir) as soon as possible, without waiting for laboratory confirmation.
For More Information
    National Association of State Public Health Veterinarians "Compendium of Measures to Prevent Disease Associated with Animals in Public Settings, 2011" is available as the first bulleted item at http://nasphv.org/documentsCompendiumAnimals.html.

Regards.
CDC HAN Team

Indiana Health Alert Network

This is an Official
Indiana Health Alert Network Advisory Message

ACTIVITY AT CRBCM

*Steady stream of patients good for business,
but Medicare and Medicaid payments still not coming in
and they accuse physicians for not wanting to take these patients;
but how can you dedicate your time fully to the complexity of taking care of patients without being paid!
It is just a shame!

*we are meeting this coming week the UTEP biostatistic lab for possible Collaboration on future research projects.
The Dept of Defense is calling for submissions. Please Rush and participate!  Closing door Feb 27, 2013.

*There are only 2 PET scan Machines in El Paso. Population 750,000, 4th city in Texas!   Price range per study from $1,500 to 4,000 according to your insurance!  Investors contact me. I will help!  Even the University Medical Center does not have (one from sure source)!

*The Great State of Indiana is UP! we will be traveling there tomorrow to take the Pulse!

*Survivorship program for cancer survivors in Indiana, coming soon!  We keep working Hard!